2022
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Rothberg BE, Schalper KA, Herbst RS, Wilson FH. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. Clinical Cancer Research 2022, 28: 3091-3103. PMID: 35247929, PMCID: PMC9288503, DOI: 10.1158/1078-0432.ccr-21-4291.Peer-Reviewed Original ResearchConceptsLung adenocarcinomaSmoking historyPack-year smoking historyMinimal smoking historySubset of patientsPancreatic ductal adenocarcinoma cell linesPotential treatment strategyTight junction protein occludinJunction protein occludinWhole-exome sequencingAdenocarcinoma cell lineAdvanced malignanciesCancer Genome AtlasRaf-MEKAdvanced tumorsMultiple malignanciesTreatment strategiesKRAS mutationsTherapeutic strategiesTherapeutic targetOncogenic RAS SignalingRelated commentaryOncogenic driversMEK inhibitionOncogenic alterations
2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria
2019
Larotrectinib in NTRK-Rearranged Solid Tumors
Wilson FH, Herbst RS. Larotrectinib in NTRK-Rearranged Solid Tumors. Biochemistry 2019, 58: 1555-1557. PMID: 30865435, PMCID: PMC7356829, DOI: 10.1021/acs.biochem.9b00126.Peer-Reviewed Original Research
2018
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne P. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research 2018, 24: 5963-5976. PMID: 30072474, PMCID: PMC6279568, DOI: 10.1158/1078-0432.ccr-18-0876.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorCrizotinibDisease Models, AnimalDNA Copy Number VariationsDrug Resistance, NeoplasmExonsGene AmplificationGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceLung NeoplasmsMiceModels, BiologicalMutationPhosphatidylinositol 3-KinasesPositron Emission Tomography Computed TomographyProtein Kinase InhibitorsProto-Oncogene Proteins c-metProto-Oncogene Proteins p21(ras)Signal TransductionXenograft Model Antitumor AssaysConceptsNon-small cell lung cancerMutant non-small cell lung cancerCell lung cancerPatient-derived cell linesCrizotinib resistanceLung cancerCell linesLong-term efficacyPI3KEGFR ligandsPI3K inhibitionCombination therapyEffective therapyMET inhibitorsSuperior efficacyPatient tumorsDrug combinationsMET inhibitionTherapeutic strategiesParental cell lineMEK inhibitionDrug resistanceRecurrent genetic eventsK inhibitionCompensatory inductionERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation
Wilson FH, Politi K. ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discovery 2018, 8: 676-678. PMID: 29858224, PMCID: PMC6330656, DOI: 10.1158/2159-8290.cd-18-0368.Commentaries, Editorials and Letters
2017
Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study
Ghazani AA, Oliver NM, St. Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Jänne P, Garraway LA, Wagle N. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics In Medicine 2017, 19: 787-795. PMID: 28125075, DOI: 10.1038/gim.2016.191.Peer-Reviewed Original ResearchConceptsClinical evidenceCancer precision medicineWhole-exome sequencing dataPrecision medicineMolecular tumor boardTumor biopsy samplesGerm-line alterationsGerm-line variantsProtocol-based approachPrecision medicine studiesMetastatic colorectalPatient preferencesTumor boardLung adenocarcinomaClinical careBlood samplesBiopsy samplesClinical relevanceClinical teamClinical meaningTherapeutic relevanceUnknown significanceVariant reviewMedicine studiesGenomic alterations
2016
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 2016, 351: 1214-1218. PMID: 26912360, PMCID: PMC4997612, DOI: 10.1126/science.aad5214.Peer-Reviewed Original ResearchConceptsProtein arginine methyltransferase 5Methylthioadenosine phosphorylaseCancer cell linesMultiple cancer lineagesPutative drug targetsCell linesTumor suppressor geneComprehensive genomic profilingCancer cell dependenciesEnzyme methylthioadenosine phosphorylaseArginine methyltransferaseCancer lineagesFunctional characterizationCancer dependenciesPRMT5 inhibitorsSuppressor geneDrug targetsTherapeutic strategiesPreferential impairmentMTAP deletionEnzymatic activityGenomic alterationsGenomic profilingCell dependencyCancer cells
2015
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA. A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell 2015, 27: 397-408. PMID: 25759024, PMCID: PMC4398996, DOI: 10.1016/j.ccell.2015.02.005.Peer-Reviewed Original ResearchConceptsFunctional genetic studiesG protein-coupled receptorsResistance driversALK inhibitionFunctional landscapeGenetic studiesLung cancer cellsALK inhibitor resistanceResistance pathwaysMechanisms of resistanceReceptor familyPKC activationPurinergic receptor familyPKC inhibitionCrizotinib-resistant ALKCancer cellsInhibitor resistanceGene signatureDependent mechanismLung cancerLung tumorsALK inhibitorsInhibitionALKMechanism
2014
Genetic modifiers of EGFR dependence in non-small cell lung cancer
Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: 18661-18666. PMID: 25512530, PMCID: PMC4284598, DOI: 10.1073/pnas.1412228112.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungCell Line, TumorErbB ReceptorsGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansLung NeoplasmsMAP Kinase Signaling SystemMembrane GlycoproteinsProtein-Tyrosine KinasesProto-Oncogene Proteins c-mosProto-Oncogene Proteins c-rafReceptor Protein-Tyrosine KinasesReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2Receptor, trkAReceptor, trkBConceptsEpidermal growth factor receptorEGFR dependenceMEK-ERKUnbiased gene expression profilingGenetic modifiersEGFR-independent activationKinase-related genesGene expression profilingEGFR-mutant NSCLC cellsGrowth factor receptorGenetic basisKinase geneEGFR activityGenesPI3K-AktAkt pathwayPC9 cellsPI3K-mTORFactor receptorKinaseNSCLC cellsKinase inhibitorsCombined inhibitionMutationsCells
2012
Administration of Vincristine in a Patient with Machado-Joseph Disease
Colpo A, Wilson FH, Nardi V, Hochberg E. Administration of Vincristine in a Patient with Machado-Joseph Disease. Oncology 2012, 82: 165-167. PMID: 22433430, PMCID: PMC3701890, DOI: 10.1159/000336602.Peer-Reviewed Original ResearchConceptsMachado-Joseph diseaseChemotherapy-induced peripheral neurotoxicityDose-limiting side effectVinca alkaloidsSevere vincristine neurotoxicityAdministration of vincristinePeripheral neurotoxicitySpinocerebellar ataxia type 3Vincristine neurotoxicityNeurological symptomsAtaxia type 3Side effectsHereditary neuropathyAntineoplastic drugsType 3NeurotoxicityDiseaseSignificant numberNeuropathyExacerbationPatientsVincristineSymptomsAdministration
2010
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells
Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2010, 117: 2567-2576. PMID: 21068437, PMCID: PMC3062351, DOI: 10.1182/blood-2010-07-295238.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Diamond-BlackfanAnemia, MacrocyticAnimalsBenzothiazolesCell CycleCell LineageCell NucleolusChromosome DeletionChromosomes, Human, Pair 5Cyclin-Dependent Kinase Inhibitor p21Erythroid Precursor CellsHaploinsufficiencyHematopoiesisHumansImidazolesMiceMice, Inbred BALB CMyelodysplastic SyndromesPiperazinesProtein BindingProto-Oncogene Proteins c-mdm2Ribosomal ProteinsRNA, Small InterferingTolueneTumor Suppressor Protein p53ConceptsErythroid progenitor cellsDiamond-Blackfan anemiaMyelodysplastic syndromeProgenitor cellsInduction of p53Bone marrow biopsyErythroid lineageNuclear p53 stainingFailure of erythropoiesisBone marrow failureHuman erythroid progenitor cellsMarrow biopsyHematopoietic progenitor cellsP53 stainingHuman hematopoietic progenitor cellsCell cycle arrestPharmacologic inhibitionMarrow failureNutlin-3Consequent cell cycle arrestP53 pathwayCycle arrestSelective impairmentExpression of shRNAsP53
2007
An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis
Ring AM, Leng Q, Rinehart J, Wilson FH, Kahle KT, Hebert SC, Lifton RP. An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 4025-4029. PMID: 17360471, PMCID: PMC1803763, DOI: 10.1073/pnas.0611728104.Peer-Reviewed Original ResearchConceptsIntravascular volume depletionNa-Cl cotransporterAldosterone signalingPseudohypoaldosteronism type IIVolume depletionPhysiologic responsesNaCl reabsorptionPHAII-mutant WNK4Steroid hormone aldosteroneRenal outer medullaryRenal NaCl reabsorptionFunctional stateWNK4 mutationsROMK activityHormone aldosteroneOuter medullaryHyperkalemiaSecretionKidneyWild-type WNK4ReabsorptionAldosteroneChannel activityChannel ENaCWNK4
2005
Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch
Kahle KT, Wilson FH, Lifton RP. Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch. Trends In Endocrinology And Metabolism 2005, 16: 98-103. PMID: 15808806, DOI: 10.1016/j.tem.2005.02.012.Peer-Reviewed Original ResearchConceptsWNK kinasesSerine-threonine kinaseNovel molecular switchSubstitution of cysteinePhysiological regulatory pathwaysRecent physiological workMolecular genetic studiesCatalytic domainSubdomain IIRegulatory pathwaysIon flux pathwaysMolecular switchWNK4 kinaseKinasePhysiological workBasolateral membranePathwayIon transport pathwaysTransport pathwaysWNK4Electrolyte homeostasisProminent roleSyndrome of hypertensionWNK1Key component
2004
A Cluster of Metabolic Defects Caused by Mutation in a Mitochondrial tRNA
Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A Cluster of Metabolic Defects Caused by Mutation in a Mitochondrial tRNA. Science 2004, 306: 1190-1194. PMID: 15498972, PMCID: PMC3033655, DOI: 10.1126/science.1102521.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingAnticodonBody Mass IndexCluster AnalysisCytidineExtrachromosomal InheritanceFemaleHumansHypercholesterolemiaHypertensionMagnesiumMaleMetabolic SyndromeMiddle AgedMitochondriaMitochondria, MuscleMuscle Fibers, SkeletalMutationPedigreePhenotypeRNARNA, MitochondrialRNA, Transfer, IleSyndromeThymidineUridineWNK kinases: molecular regulators of integrated epithelial ion transport
Kahle KT, Wilson FH, Lalioti M, Toka H, Qin H, Lifton RP. WNK kinases: molecular regulators of integrated epithelial ion transport. Current Opinion In Nephrology & Hypertension 2004, 13: 557-562. PMID: 15300163, DOI: 10.1097/00041552-200409000-00012.Peer-Reviewed Original ResearchConceptsPseudohypoaldosteronism type IIWNK kinasesPotassium ion channelsChloride ion fluxIon channelsSerine-threonine kinaseCoordinated regulationDiverse epitheliaMolecular regulatorsMolecular switchKinasePotassium ion secretionDynamic regulatorGeneral roleDisease physiologyIon fluxIntegrated regulationElectrolyte homeostasisEpithelial ion transportEpithelial transportersEssential roleWNK4HomeostasisFlux pathwaysMutationsWNK4 regulates apical and basolateral Cl– flux in extrarenal epithelia
Kahle KT, Gimenez I, Hassan H, Wilson FH, Wong RD, Forbush B, Aronson PS, Lifton RP. WNK4 regulates apical and basolateral Cl– flux in extrarenal epithelia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 2064-2069. PMID: 14769928, PMCID: PMC357052, DOI: 10.1073/pnas.0308434100.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCarrier ProteinsCell PolarityChloridesEpitheliumHumansImmunohistochemistryIon TransportKidneyMembrane ProteinsMembrane Transport ProteinsMiceOocytesProtein Serine-Threonine KinasesRNA, MessengerSodium-Potassium-Chloride SymportersSolute Carrier Family 12, Member 2Sulfate TransportersXenopus laevisConceptsCl fluxBlood-brain barrierUnrelated ion channelsActivity of mediatorsWNK4 mRNABile ductPancreatic ductExtrarenal expressionExtrarenal tissuesCl(-) handlingPseudohypoaldosteronism type IIChannel ROMKNaCl reabsorptionSerine-threonine kinase WNK4Specialized endotheliumExchanger SLC26A6NaCl cotransporterWNK4 effectsColonic cryptsEpitheliumVariable inhibitionSweat ductsTight junctionsKidneyElectrolyte flux
2002
Salt and blood pressure: new insight from human genetic studies.
Lifton RP, Wilson FH, Choate KA, Geller DS. Salt and blood pressure: new insight from human genetic studies. Cold Spring Harbor Symposia On Quantitative Biology 2002, 67: 445-50. PMID: 12858570, DOI: 10.1101/sqb.2002.67.445.Books
2001
Human Hypertension Caused by Mutations in WNK Kinases
Wilson F, Disse-Nicodème S, Choate K, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford D, Lipkin G, Achard J, Feely M, Dussol B, Berland Y, Unwin R, Mayan H, Simon D, Farfel Z, Jeunemaitre X, Lifton R. Human Hypertension Caused by Mutations in WNK Kinases. Science 2001, 293: 1107-1112. PMID: 11498583, DOI: 10.1126/science.1062844.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceBase SequenceChromosome MappingChromosomes, Human, Pair 12Chromosomes, Human, Pair 17CytoplasmFemaleGene Expression Regulation, EnzymologicGenetic LinkageHumansHypertensionIntercellular JunctionsIntracellular Signaling Peptides and ProteinsIntronsKidney Tubules, CollectingKidney Tubules, DistalMaleMembrane ProteinsMicroscopy, FluorescenceMinor Histocompatibility AntigensMolecular Sequence DataMutationMutation, MissensePedigreePhosphoproteinsProtein Serine-Threonine KinasesPseudohypoaldosteronismSequence DeletionSignal TransductionWNK Lysine-Deficient Protein Kinase 1Zonula Occludens-1 ProteinConceptsMajor public health problemPublic health problemRenal salt reabsorptionAntihypertensive drugsHuman hypertensionUnknown causeDistal nephronKidney segmentsPseudohypoaldosteronism type IIHealth problemsSalt reabsorptionHypertensionWNK1 expressionNew targetsWNK kinasesTight junctionsType IISerine-threonine kinaseIntronic deletionWNK4WNK familyMutationsWNK1KinaseExcretion
1999
Molecular cloning and functional characterization of KCC3, a new K-Cl cotransporter
Race J, Makhlouf F, Logue P, Wilson F, Dunham P, Holtzman E. Molecular cloning and functional characterization of KCC3, a new K-Cl cotransporter. American Journal Of Physiology 1999, 277: c1210-c1219. PMID: 10600773, DOI: 10.1152/ajpcell.1999.277.6.c1210.Peer-Reviewed Original ResearchMeSH KeywordsBiological TransportCarrier ProteinsCell LineChlorineChromosome MappingCloning, MolecularDNA PrimersEthylmaleimideGene ExpressionHumansKidneyMolecular Sequence DataOsmosisPhylogenyPlacentaPotassiumProtein Structure, TertiarySequence Homology, Amino AcidSulfhydryl ReagentsSymportersTransfectionConceptsCation-chloride cotransporter familyK-Cl cotransporterNa-Cl cotransporterTransmembrane domain 5Large extracellular loopStimulation of cotransportAmino acid levelsHydropathy analysisDeduced proteinHuman embryonic kidneyNa-K-Cl cotransporterTransmembrane domainMolecular cloningK-Cl cotransportFunctional characterizationCotransporter familyExtracellular loopEmbryonic kidneyDomain 5Amino acidsKCC3Human placentaAcid levelsSkeletal muscleCotransporter